Early CVOTs on GLP-1RAs, such as the LEADER, Harmony Outcomes, REWIND, and SUSTAIN-6 trials, focused on patients with T2DM and demonstrated the cardioprotective effects of these agents, including liraglutide, albiglutide, dulaglutide, and semaglutide.[811] The potential cardiovascular benefits of GLP-1RAs in patients without diabetes remain an active area of research
They can help you determine the best approach for managing your psoriatic arthritis and any other health conditions
In addition, hyperinsulinemia in diabetic patients seems to be the main reason for an increased risk of cancer (204)
That's why her approach to healthy weight loss involves more than medication
Contact Our Chicago Product Liability Lawyers The manufacturers of GLP-1 medications have denied wrongdoing and pledged to aggressively defend against legal claims tied to their dangerous drugs
These preclinical findings support clinical trial results showing that tirzepatide, a dual GIPR/GLP-1R agonist, exhibits greater anti-obesity effects than GLP-1 receptor agonists alone